Struggling Intercell replaces its CEO

After stumbling badly in the clinic, Austria's Intercell announced that CEO Gerd Zettlmeissl has abruptly resigned and been replaced by COO Thomas Lingelbach. Late last year shares of Intercell AG, the last of the independent vaccine makers, cratered after the company announced that it was forced to toss its late-stage vaccine patch project for travelers' diarrhea on the scrap heap after a pair of clinical trials flunked their primary endpoints. The trial failure triggered a company-wide restructuring. Intercell release

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.